약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 2.

Table. 2.

Patient characteristics at baseline

EMPA-REG OUTCOME6) EMEPEROR-Reduced7) EMEPEROR-Preserved8) EMPULSE34)
Empagliflozin Placebo Empagliflozin 10 mg Placebo Empagliflozin 10 mg Placebo Empagliflozin 10 mg Placebo
10 mg 25 mg
Total number of patients 7,020 3,730 5,988 530
2,345 2,342 2,333 1,863 1,867 2,997 2,991 265 265
Age, years (mean±SD) 63.0±8.6 63.2±8.6 63.2±8.8 67.2±10.8 66.5±11.2 71.8±9.3 71.9±9.6 71 70
Female, n (%) 692(29.5) 659(28.1) 653(28) 437(23.5) 456(24.4) 1,338(44.6) 1,338(44.7) 86(32.5) 93(35.1)
NYHA Class II, n (%) - - - 1,399 (75.1) 1,401 (75) 2,432 (81.1) 2,451 (81.9) 95 (35.8) 91 (34.3)
NYHA Class III, n (%) - - - 455 (24.4) 455 (24.4) 552 (18.4) 531 (17.8) 134 (50.6) 145 (54.7)
NYHA Class IV, n (%) - - - 9 (0.5) 11 (0.6) 10 (0.3) 8 (0.3) 26 (9.8) 23 (8.7)
BMI, kg/m2 (mean±SD, or mean [range]) 30.6±5.2 30.6±5.3 30.7±5.2 28±5.5 27.8±5.3 29.8±5.8 29.9±5.9 28.4(24.5-32.5) 29.1(24.7-33.6)
LVEF, % (mean±SD, or mean [range]) - - - 27.7±6 27.2±6.1 54.3±8.8 54.3±8.8 31(23-45) 32(22.5-49)
HFH history, n (%) - - - 577 (31) 574 (30.7) 699 (23.3) 670 (22.4) - -
DM, n (%) 2,345(100) 2,342(100) 2,333(100) 927(49.8) 929(49.8) 1,466(48.9) 1,472(49.2) 124(46.8) 116(43.8)
eGFR, mL/min/1.73m2 (mean±SD, or mean [range]) 74.3±21.8 74±21.4 73.8±21.1 61.8±21.7 62.2±21.5 60.6±19.8 60.6±19.9 50(36-65) 54.3(39-70)

BMI: body mass index; DM: diabetes mellitus; eGFR: estimated glomerular filtration rate; HFH: heart failure hospitalization; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association; SD: standard deviation

Yakhak Hoeji 2022;66:175-83 https://doi.org/10.17480/psk.2022.66.4.175
© 2022 Yakhak Hoeji